media – Page 34 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field

Lumay Pharmaceutical(300006) announced on March 12 that the company recently signed an agreement with Xi’an Wojie Private Equity Fund Management Co., Ltd. and Sansure Biotech.Several institutions, including a technology company, signed a partnership agreement to jointly establish Guangzhou Shengquan Baijie Venture Capital Fund Partnership (Limited Partnership). The fund aims to raise a total of RMB 150 million, of which the company, as a limited partner, will contribute RMB 5 million from its own funds, representing a 3.33% stake. The investment fund primarily invests in innovative biopharmaceuticals and medical devices .In vitro diagnosticsIn the life and health sectors, investments in these industries shall not be less than 60% of the fund’s total paid-in capital. The fund focuses on investing in Guangzhou’s strategic emerging industries and future industries, and has established a fund for seed companies in Guangzhou.Investment ratio requirements for early-stage and angel-stage projects. According to the announcement, the company’s investment ...
- Source: drugdu
- 127
- March 12, 2026
Huadong Medicine’s clinical trial application for injectable HDM2024 drug has been approved by the US FDA

March 11, Huadong Medicine…(000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd. (hereinafter referred to as “Sino-American East China”), received a notification from the U.S. Food and Drug Administration (hereinafter referred to as “FDA”) that the clinical trial application for injectable HDM2024 submitted by Sino-American East China has been approved by the U.S. FDA and can be carried out in the United States for Phase I clinical trials, with the indication being advanced solid tumors. Huadong Medicine stated that the approval of the US clinical trial of injectable HDM2024 is another important step in the product’s development process and will further enhance the company’s core competitiveness in the field of oncology treatment. https://finance.eastmoney.com/a/202603113668988846.html
- Source: drugdu
- 125
- March 12, 2026
Its subsidiary’s Class 1 innovative drug TQB3205 has been approved for clinical trials, intended for the treatment of advanced malignant tumors.

On March 11, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.TQB3205 has received clinical trial approval from the China National Medical Products Administration and is intended for the treatment of advanced malignant tumors. TQB3205 is an oral pan-KRAS inhibitor that effectively inhibits the proliferation of various KRAS-mutated tumor cells. The company will accelerate the clinical development of TQB3205, aiming to overcome existing treatment limitations and bring new treatment options to a wider range of patients with KRAS-mutated advanced malignancies. https://finance.eastmoney.com/a/202603113668972521.html
- Source: drugdu
- 139
- March 12, 2026
HOSPITALAR

Organiser：Informa Markets Time：May 19 – May 22, 2026 Address：Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1.5, São Paulo – SP Exhibition hall：São Paulo Expo Product range: Medical Equipment Pavilion: Hospital technical facilities and equipment; medical clinic technology and equipment; ward furniture and equipment; diagnostic and therapeutic equipment; biochemical and testing equipment; pharmaceutical products; sanitary materials; medical communication technology and equipment; comprehensive hospital information technology and services Rehabilitation Technology for the Disabled Pavilion: Nursing equipment; nursing products; communication technology; mobile nursing; nursing services; medical technology; orthopedic surgical technology; outpatient nursing; physiotherapy; prosthetics; services; ergonomic therapy; communication technology; wheelchairs Pharmaceutical Pavilion: Prescription drugs; traditional Chinese patent medicines; western medicines; antibiotics; powder injections; infusions; tablets; ointments; capsules; various new drugs; special drugs; national traditional Chinese medicine protected varieties; national basic medical insurance drugs; pharmaceutical raw materials; various intermediates; biochemical drug reagents and vaccines; various biological products Dental Pavilion: Dental instruments & ...
- Source: drugdu
- 168
- March 12, 2026
【EXPERT Q&A】How to apply for a medical device business license?

Drugdu.com expert’s response: Process and Required Materials for Applying for a Medical Device Operating License I. Application Process Online Application (1-2 Days) Log in to the “Food and Drug Regulatory Information Platform” of the National Medical Products Administration (NMPA) to submit the application. Register an enterprise account in advance, and clearly indicate “Third-Class Medical Device Operation” in the business scope. Material Preparation (7-15 Days) Core materials include: Enterprise business license副本 (copy, must include medical device business scope); Identity certificates and academic/professional qualification certificates (in medical-related fields) of the legal representative and quality manager; Property ownership certificate or lease contract for the business premises (warehouse area for third-class devices ≥ 15㎡); Medical device product registration certificates, manufacturer authorization letters, and business licenses; Quality management system documents (templates for 11 systems including procurement, acceptance, and warehousing). Tips to Avoid Pitfalls: Materials must be stamped with the official seal, and electronic document naming ...
- Source: drugdu
- 138
- March 11, 2026
Novogene® has been approved, making its global debut in China!

Recently, the National Medical Products Administration (NMPA) officially approved the marketing application of Novogene® (insulin smegglutide injection) in China. Novogene® is the world ‘s first and currently only approved basal insulin/glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly formulation. It consists of the world’s first insulin weekly formulation, insulin smegglutide, and the globally widely used GLP-1RA weekly formulation, smegglutide[1]. It is suitable for adult patients with type 2 diabetes whose blood glucose control is poor after basal insulin or GLP-1RA treatment, and is used in combination with oral hypoglycemic drugs on the basis of diet and exercise [2] . Multidimensional blood glucose management and Patient treatment adherence remains high in type 2 diabetes. Key challenges in treatment ﹀ There are approximately 589 million adults with diabetes worldwide, of whom more than 90% have type 2 diabetes [3] . Insulin therapy is the cornerstone of diabetes management [4] , but in clinical practice, ...
- Source: drugdu
- 157
- March 10, 2026
CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China.

On March 5, CSPC Pharmaceutical Group (1093.HK) announced that…The indacaterol mometasone inhalation powder developed by our Group (hereinafter referred to as “the Product”) has been approved by the National Medical Products Administration and can be used for clinical trials in China.This product is used for maintenance treatment of asthma in adults and adolescents aged 12 years and older. Indacaterol is a long-acting β2-adrenergic agonist (LABA) with smooth muscle relaxant and bronchodilator effects. Mometasone furoate is an inhaled corticosteroid (ICS) with local anti-inflammatory effects. Indacaterol-Mometasone Inhalation Powder is the first once-daily inhaled ICS-LABA dual-combination inhaled formulation included in the National Medical Insurance Catalog (2022 Edition), providing asthma patients with a more efficient and convenient treatment option. The approval of the clinical trial for this product is another important achievement of the Group’s high-end innovative inhalation technology platform, laying a solid foundation for the development of subsequent inhalation formulations in the pipeline. ...
- Source: drugdu
- 129
- March 10, 2026
Hengrui Medicine subsidiary’s HRS9531 injection has been approved for clinical use in chronic kidney disease

On March 9, Hengrui Medicine (600276/01276) issued an announcement stating that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HRS9531 injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future. The application for this drug was for clinical trials, with application numbers CXHL2501355 and CXHL2501356. The approval conclusion indicated that the application met the relevant requirements for drug registration and approved the commencement of clinical trials for chronic kidney disease. HRS9531 injection is a globally proprietary intellectual property.This novel dual agonist targeting both gastric inhibitory peptide receptor and glucagon-like peptide-1 receptor has the effects of regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity. To date, the cumulative R&D investment in HRS9531-related projects is approximately RMB 632 million (unaudited). The company reminds investors that the drug development and market launch process is lengthy ...
- Source: drugdu
- 178
- March 10, 2026
Junshi Biosciences’ marketing application for toripalimab injection (subcutaneous injection) has been accepted

On the evening of March 9 that Junshi Biosciences (688180) issued an announcement stating that the company received an “Acceptance Notice” issued by the National Medical Products Administration, and the marketing application for 12 indications of the company’s product, toripalimab injection (subcutaneous injection), for the treatment of tumors has been accepted. Junshi Biosciences stated that JS001sc is a subcutaneous injection formulation developed by the company based on its already marketed product, toripalimab injection. It is the first domestically produced anti-PD-1 monoclonal antibody subcutaneous injection formulation to enter the marketing application stage, and is expected to bring convenience to patients. The 12 indications listed in this marketing application for JS001sc are all the indications currently approved for toripalimab injection in mainland China. https://finance.eastmoney.com/a/202603093666384241.html
- Source: drugdu
- 153
- March 10, 2026
ATTC Platform Shines

On March 5, Hutchison MediPharma announced its financial results for 2025. The market sales of four oncology products (fruquintinib, surufatinib, cevotinib, and tazestat) reached $524.7 million, a 5% increase. Sales in the second half of the year were up 24% compared to the first half of 2025. the core product , fruquintinib (FRUZAQLA), increased by 26% to $366.2 million overseas , primarily driven by strong growth following approval in 38 countries, including approval in more than 15 countries by 2025. Further reimbursement coverage is also progressing steadily, with the product currently included in health insurance programs in nearly 20 countries. of fruquintinib were $100.1 million , down from $115 million in 2024. Other oncology/immunology revenue (including upfront payments, regulatory milestone payments, R&D services, and licensing revenue) was $71.1 million. Other revenue (primarily from prescription drug distribution) remained stable at $263 million. Total consolidated revenue was $548.5 million. In addition, Hutchison ...
- Source: drugdu
- 135
- March 10, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.